vs
Side-by-side financial comparison of AbbVie (ABBV) and SELECT MEDICAL HOLDINGS CORP (SEM). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $1.4B, roughly 11.9× SELECT MEDICAL HOLDINGS CORP). AbbVie runs the higher net margin — 10.9% vs 1.4%, a 9.5% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs 6.4%). AbbVie produced more free cash flow last quarter ($4.9B vs $5.2M). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 2.8%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Select Medical is a healthcare company based in Pennsylvania. It owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics. Select Medical is a subsidiary of Select Medical Holdings, which is listed on the New York Stock Exchange.
ABBV vs SEM — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $1.4B |
| Net Profit | $1.8B | $20.2M |
| Gross Margin | 72.6% | — |
| Operating Margin | 27.3% | 4.6% |
| Net Margin | 10.9% | 1.4% |
| Revenue YoY | 10.0% | 6.4% |
| Net Profit YoY | 8354.5% | 225.7% |
| EPS (diluted) | $1.02 | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $1.4B | ||
| Q3 25 | $15.8B | $1.4B | ||
| Q2 25 | $15.4B | $1.3B | ||
| Q1 25 | $13.3B | $1.4B | ||
| Q4 24 | $15.1B | $1.3B | ||
| Q3 24 | $14.5B | $1.3B | ||
| Q2 24 | $14.5B | $1.3B | ||
| Q1 24 | $12.3B | $1.3B |
| Q4 25 | $1.8B | $20.2M | ||
| Q3 25 | $186.0M | $28.8M | ||
| Q2 25 | $938.0M | $40.6M | ||
| Q1 25 | $1.3B | $56.7M | ||
| Q4 24 | $-22.0M | $-16.1M | ||
| Q3 24 | $1.6B | $55.6M | ||
| Q2 24 | $1.4B | $77.6M | ||
| Q1 24 | $1.4B | $96.9M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | 4.6% | ||
| Q3 25 | 12.1% | 5.4% | ||
| Q2 25 | 31.7% | 6.5% | ||
| Q1 25 | 28.0% | 8.3% | ||
| Q4 24 | -9.9% | 1.6% | ||
| Q3 24 | 26.5% | 4.3% | ||
| Q2 24 | 27.6% | 5.8% | ||
| Q1 24 | 22.7% | 9.0% |
| Q4 25 | 10.9% | 1.4% | ||
| Q3 25 | 1.2% | 2.1% | ||
| Q2 25 | 6.1% | 3.0% | ||
| Q1 25 | 9.6% | 4.2% | ||
| Q4 24 | -0.1% | -1.2% | ||
| Q3 24 | 10.8% | 4.4% | ||
| Q2 24 | 9.5% | 6.1% | ||
| Q1 24 | 11.1% | 7.3% |
| Q4 25 | $1.02 | $0.17 | ||
| Q3 25 | $0.10 | $0.23 | ||
| Q2 25 | $0.52 | $0.32 | ||
| Q1 25 | $0.72 | $0.44 | ||
| Q4 24 | $-0.03 | $-0.12 | ||
| Q3 24 | $0.88 | $0.43 | ||
| Q2 24 | $0.77 | $0.60 | ||
| Q1 24 | $0.77 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $26.5M |
| Total DebtLower is stronger | $58.9B | $1.8B |
| Stockholders' EquityBook value | $-3.3B | $1.7B |
| Total Assets | $134.0B | $5.9B |
| Debt / EquityLower = less leverage | — | 1.06× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $26.5M | ||
| Q3 25 | $5.7B | $60.1M | ||
| Q2 25 | $6.5B | $52.3M | ||
| Q1 25 | $5.2B | $53.2M | ||
| Q4 24 | $5.6B | $59.7M | ||
| Q3 24 | $7.3B | $191.5M | ||
| Q2 24 | $13.2B | $111.2M | ||
| Q1 24 | $18.1B | $92.6M |
| Q4 25 | $58.9B | $1.8B | ||
| Q3 25 | $63.0B | $1.7B | ||
| Q2 25 | $63.0B | $1.8B | ||
| Q1 25 | $64.5B | $1.8B | ||
| Q4 24 | $60.3B | $1.7B | ||
| Q3 24 | $58.5B | $3.1B | ||
| Q2 24 | $58.0B | $3.6B | ||
| Q1 24 | $63.8B | $3.8B |
| Q4 25 | $-3.3B | $1.7B | ||
| Q3 25 | $-2.6B | $1.7B | ||
| Q2 25 | $-183.0M | $1.7B | ||
| Q1 25 | $1.4B | $1.7B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $6.0B | $1.9B | ||
| Q2 24 | $6.8B | $1.4B | ||
| Q1 24 | $8.0B | $1.4B |
| Q4 25 | $134.0B | $5.9B | ||
| Q3 25 | $133.9B | $5.7B | ||
| Q2 25 | $137.2B | $5.7B | ||
| Q1 25 | $136.2B | $5.7B | ||
| Q4 24 | $135.2B | $5.6B | ||
| Q3 24 | $143.4B | $8.0B | ||
| Q2 24 | $141.9B | $7.9B | ||
| Q1 24 | $148.9B | $7.9B |
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | 45.44× | 1.03× | ||
| Q4 24 | 18.15× | 1.01× | ||
| Q3 24 | 9.70× | 1.62× | ||
| Q2 24 | 8.56× | 2.54× | ||
| Q1 24 | 7.97× | 2.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $64.3M |
| Free Cash FlowOCF − Capex | $4.9B | $5.2M |
| FCF MarginFCF / Revenue | 29.4% | 0.4% |
| Capex IntensityCapex / Revenue | 2.0% | 4.2% |
| Cash ConversionOCF / Net Profit | 2.87× | 3.19× |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | $117.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $64.3M | ||
| Q3 25 | $7.0B | $175.3M | ||
| Q2 25 | $5.2B | $110.3M | ||
| Q1 25 | $1.6B | $-3.5M | ||
| Q4 24 | $7.0B | $125.4M | ||
| Q3 24 | $5.4B | $181.0M | ||
| Q2 24 | $2.3B | $278.2M | ||
| Q1 24 | $4.0B | $-66.7M |
| Q4 25 | $4.9B | $5.2M | ||
| Q3 25 | $6.6B | $122.2M | ||
| Q2 25 | $4.9B | $45.6M | ||
| Q1 25 | $1.4B | $-55.8M | ||
| Q4 24 | $6.8B | $62.0M | ||
| Q3 24 | $5.2B | $130.3M | ||
| Q2 24 | $2.0B | $222.6M | ||
| Q1 24 | $3.8B | $-119.2M |
| Q4 25 | 29.4% | 0.4% | ||
| Q3 25 | 42.1% | 9.0% | ||
| Q2 25 | 31.7% | 3.4% | ||
| Q1 25 | 10.5% | -4.1% | ||
| Q4 24 | 44.7% | 4.7% | ||
| Q3 24 | 35.9% | 10.2% | ||
| Q2 24 | 14.0% | 17.4% | ||
| Q1 24 | 31.3% | -9.0% |
| Q4 25 | 2.0% | 4.2% | ||
| Q3 25 | 2.4% | 3.9% | ||
| Q2 25 | 1.7% | 4.8% | ||
| Q1 25 | 1.8% | 3.9% | ||
| Q4 24 | 1.9% | 4.8% | ||
| Q3 24 | 1.7% | 4.0% | ||
| Q2 24 | 1.7% | 4.3% | ||
| Q1 24 | 1.6% | 4.0% |
| Q4 25 | 2.87× | 3.19× | ||
| Q3 25 | 37.76× | 6.09× | ||
| Q2 25 | 5.49× | 2.72× | ||
| Q1 25 | 1.27× | -0.06× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | 3.25× | ||
| Q2 24 | 1.66× | 3.59× | ||
| Q1 24 | 2.95× | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
